[由于V因子异常而引起的抗凝功能变化的阐释以及对血栓友爱症的简单查试验的开发]
Naruto Shimonishi1,2, Keiji Nogami2
1The Course of Thrombosis and Hemostasis Molecular Pathology, Nara Medical University.
概括
凝血因子V (FV) 异常可能导致出血或血栓形成. 研究人员在日本发现了一种新的FV突变 (FV-W1920R),导致深静脉血栓塞 (DVT),挑战了以前的信念.
科学领域:
- 血液学 血液学 血液学
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 凝血因子V (FV) 具有前凝和抗凝作用.
- 先天性FV异常,通常是由于基因突变,通常表现为出血障碍.
- FV-R506Q (FV Leiden) 是一种常见的异常,与深静脉血栓症 (DVT) 相关,原因是活性蛋白C (APC) 裂变受损.
研究的目的:
- 为了调查日本首次报告的FV异常相关血栓瘤病例.
- 确定FV异常相关血栓的遗传基础和致病机制.
- 开发一种针对FV缺陷和APC耐药性的新型诊断试验.
主要方法:
- 基因分析以确定FV基因中的突变.
- 功能性测试以评估FV抗凝剂活性和APC耐药性.
- 开发一种使用重组血栓模块的新型凝块波形分析试验.
主要成果:
- 一种位于C1域的新型FV突变FV-W1920R (FVNara) 被确定为日本患者复发性DVT的原因.
- 这种突变与已知的APC切割部位突变不同.
- 成功开发了一种用于快速检测具有APC耐药性的FV缺陷的新试验.
结论:
- 与FV相关的血栓形成倾向可能在日本被诊断不足.
- 新的FV-W1920R突变突出了与FV异常相关的血栓形成的新机制.
- 开发的测定为诊断与FV相关的血栓性疾病提供了一个有希望的工具.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
753
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
753
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Disorders of Hemostasis
991
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
991
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
14
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
14
Clot Retraction and Fibrinolysis
6.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.5K


